Seagen, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Seagen, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
Experimental drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to attach to cancer cells and kill them. The study aims to find a safe dose and check for side effects in …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 28, 2026 23:51 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tested a drug called tisotumab vedotin, alone or with other cancer medicines, in 350 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 28, 2026 23:50 UTC
-
New drug trial targets Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug, PF-08046052/SGN-EGFRd2, in people with advanced solid tumors that cannot be removed or have spread. The main goal is to check safety and side effects. About 68 participants with colorectal, lung, head/neck, or pancreatic cancer will take p…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC